News Servier’s $1.8bn Agios deal delivers glioma prospect IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.
News After rebuffing Biogen, Sage pairs off with Supernus Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
